JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, cilt.12, sa.1, ss.334-339, 2016 (SCI-Expanded)
Aim: Concurrent chemoradiotherapy (CRT) is the standard therapy for patients with unresectable Stage III nonsmall cell lung cancer (NSCLC). The aim of this study was to assess the efficacy and safety of concurrent CRT in unresectable Stage III NSCLC in Turkey.